Alpha 1-Antitrypsin Deficiency has active NIH research funding with 17 funded grants totaling $23.6M.
1 new grant started in the last 12 months.
1 additional grant classified as “Other” (multi-disciplinary, infrastructure, etc.).
NIH fiscal year (Oct–Sep)
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Alpha 1-Antitrypsin Deficiency. Strongest funded area: Gene Therapy / Cell Therapy. Largest gap: Biomarker / Diagnostics.
11 publications in Diagnostic / Biomarker but no NIH-funded grants found in Biomarker / Diagnostics for alpha 1-antitrypsin deficiency. Existing research activity suggests this may be a viable area for grant applications.
These grants mention Alpha 1-Antitrypsin Deficiency as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.
Track funding opportunities for Alpha 1-Antitrypsin Deficiency.
Follow this disease to be notified about new NIH grants and funding changes.
Already have an account? Sign in to manage your watchlists.